Accolate Patent Expiration

Accolate is a drug owned by Strides Pharma Global Pte Ltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 18, 2014. Details of Accolate's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5612367 Method of enhancing bioavailability of pharmaceutical agents
Mar, 2014

(10 years ago)

Expired
US5482963 Pharmaceutical agents useful as leukotriene antagonists
Jan, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Accolate is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Accolate's family patents as well as insights into ongoing legal events on those patents.

Accolate's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Accolate's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 18, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Accolate Generics:

Zafirlukast is the generic name for the brand Accolate. 4 different companies have already filed for the generic of Accolate, with Annora Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Accolate's generic

How can I launch a generic of Accolate before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Accolate's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Accolate's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Accolate -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
10 mg and 20 mg 29 Feb, 2008 1 18 Nov, 2010 18 Mar, 2014 Eligible





About Accolate

Accolate is a drug owned by Strides Pharma Global Pte Ltd. It is used for increasing the absorption of the drug substance in the body. Accolate uses Zafirlukast as an active ingredient. Accolate was launched by Strides Pharma in 1999.

Approval Date:

Accolate was approved by FDA for market use on 17 September, 1999.

Active Ingredient:

Accolate uses Zafirlukast as the active ingredient. Check out other Drugs and Companies using Zafirlukast ingredient

Treatment:

Accolate is used for increasing the absorption of the drug substance in the body.

Dosage:

Accolate is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20MG TABLET Prescription ORAL
10MG TABLET Prescription ORAL